allergan

Allergan shareholders reject proposal to split roles of chairman and CEO

pharmafile | May 2, 2019 | News story | Research and Development Allergan, Appaloosa, CEO, board of directors, hedge fund, pharma 

Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, both of which are currently held by Brent Saunders.

The proposal, put forward by hedge fund Appaloosa, was rejected by 61.3% of shareholders.

“The Allergan board appreciates the support of our shareholders reflected in the voting results” Allergan said. The motion comes after the company agreed to split the roles in the next leadership transition.

Advertisement

The firm however argued that splitting the roles immediately, as requested by Appaloosa, “could impede the board’s effectiveness by creating a crisis of confidence in Saunders at a time when leadership stability and effectiveness is critical.”

The push from Appaloosa comes after the investigational therapy rapastinel failed to improve outcomes in three late-stage studies of major depressive disorder.

The hedge fund has also pushed for a merger unless management are held to account. Allergan posted a fourth-quarter loss of $4.3 billion in the final three months of 2018.

Louis Goss

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content